SWK (SWKH) Q1 2025 earnings summary

Executive summary

• Q1 2025 GAAP net income rose to $4.5 million from $0.5 million in Q1 2024, with adjusted non-GAAP net income at $8.6 million and revenue up 3.5% to $11.8 million, driven by higher pharmaceutical development revenue and a benefit from credit losses.

• Monetized the majority of the royalty portfolio for $34.0 million in April 2025, resulting in a $3.7 million Q1 loss on revaluation and enabling a $4.00 per share special dividend.

• Paid a $4 per share special dividend in May 2025 following the royalty portfolio sale.

• Completed a $15 million financing to a life science company and closed a $15.0 million term loan commitment to ImpediMed Limited.

• Share repurchases contributed to book value per share growth, with $1.1 million repurchased year-to-date and $0.9 million during Q1 2025.

Financial highlights

• Q1 2025 revenue was $11.8 million, up from $11.4 million in Q1 2024, with GAAP net income of $4.5 million ($0.37 per diluted share) and adjusted non-GAAP net income of $8.1 million.

• GAAP book value per share increased 6.8% year-over-year to $23.94; non-GAAP tangible book value per share rose 10.5% to $21.73.

• Operating expenses dropped to $3.7 million from $10.3 million year-over-year, mainly due to lower provision for credit losses.

• Cash and cash equivalents increased to $29.8 million as of March 31, 2025, from $5.9 million at year-end 2024.

• General and administrative expenses increased by $0.6 million, mainly due to compensation and legal costs related to the royalty sale.

Outlook and guidance

• Current finance receivables portfolio of $223.1 million and $0.5 million in marketable investments expected to generate positive cash flows in 2025, with management targeting normalized annual OpEx of $8 million and bond interest expense of $3 million.

• Aiming for approximately $20 million in finance segment adjusted non-GAAP net income based on current portfolio size.

• Management continues to evaluate new investment opportunities in the life sciences sector and notes that guidance excludes potential impairments, early payoffs, or abnormal expenses.